https://doi.org/10.55788/9db303a3
“Exposure to inhaled DE has been associated with inflammatory and metabolic changes, and is linked to respiratory and cardiovascular diseases,” outlined Dr Mahadevappa Hemshekhar (University of Manitoba, Canada) [1]. “Furthermore, the severity and prevalence of these diseases are different in men and women.” However, the underlying, traffic-related, air pollution-mediated protein changes have not been thoroughly investigated. The current study aimed to assess sex-related differences in response to real-world concentrations of DE. For this purpose, participants were randomised to 4 hours of exposure to filtered air (n=5) or to 4 hours of exposure to DE (20, 50, or 150 μg PM2.5/m3; n=5 each), with a 4-week washout period and a random cross-over after which another 4-hour exposure followed [1]. After 24 hours of exposure, plasma was obtained for proteomic profiling through liquid chromatography with tandem mass spectrometry.
The results displayed that 97 proteins in men and 46 proteins in women were altered after exposure to DE. Interestingly, sex was an effect modifier of 57 proteins that were related to DE. These proteins could be organised in functional groups, such as inflammation, oxidative stress, cardiovascular diseases, and host defence peptides, and it was demonstrated that different patterns of expression could be observed for men and women. According to Dr Hemshekhar, this data demonstrates the importance of sex as a modifier of host response to air pollution and that sex is an essential factor in the understanding of the effect of traffic-related air pollution on humans.
- Hemshekhar M, et al. Plasma proteomics analysis reveals sex-related differences in response to diesel exhaust. Impact of the external and internal exposome on chronic lung disease, PA591, ERS International Congress 2022, Barcelona, Spain, 4‒6 September.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« New trends in cystic lung diseases Next Article
Intravenous N-acetylcysteine performs well in hospitalised patients »
« New trends in cystic lung diseases Next Article
Intravenous N-acetylcysteine performs well in hospitalised patients »
Table of Contents: ERS 2022
Featured articles
Letter from the Editor
COVID-19: What Is New?
Does vilobelimab reduce mortality in severe COVID-19?
Awake proning not positive in COVID-19
Favipiravir may help patients over 60 years with COVID-19 to recover
Inhaled agent under investigation for COVID-19
Accurate voice-based COVID-19 diagnostic test in development
Novel scoring tool for post-COVID syndrome aids clinicians and researchers
COPD: Therapies and Innovations
Icenticaftor achieves results on top of triple inhalation therapy in COPD
STARR2: A new approach for treating COPD exacerbations
COPD medication not effective in symptomatic smokers with preserved spirometry
Do digital tools improve physical activity in COPD?
Hyperpolarised gas MRI ready for clinical use
All About Asthma
Tezepelumab in asthma: mucus plugging down, lung function up
Digital asthma intervention improves health and reduces costs
Digitally enhanced therapy lowers treatment burden and costs in severe asthma
Mepolizumab beneficial for patients with severe eosinophilic asthma
Progress in Paediatrics
Antibiotics cause increased risk of wheezing in severe RSV bronchiolitis
Inhaled corticosteroids useful in preterms with decreased lung function
Fish oil or vitamin D during pregnancy can prevent croup
Encouraging results of nintedanib in children with fibrosing ILD
Focus on Interventional Pulmonology
Head-to-head: lung volume reduction surgery vs endobronchial valves
Durable effect of endobronchial valves in severe emphysema
Cone beam CT-guided ENB improves detection of pulmonary nodules
Confirmatory mediastinoscopy not needed in resectable NSCLC
Sleep and Breathing Disorders
In the spotlight: Cancer trends in obstructive sleep apnoea
Impact of CPAP on cardiac endpoints in OSA
Sustained hypoxaemia predicts unprovoked VTE in OSA
CPAP therapy in the prevention of cardiovascular risk in patients with OSA
Other Remarkable Research
Excellent results for high-flow nasal cannula oxygen therapy in acute respiratory failure
Antifibrotic therapy may slow down FVC decline in RAILD
Intravenous N-acetylcysteine performs well in hospitalised patients
Men and women respond differently to diesel exhaust
New trends in cystic lung diseases
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com